Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Share-based Compensation data on file, last reported at $3.9 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 21.88% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $12.6 million, a 8.95% decrease from a year earlier, with the FY2025 full-year figure at $22.1 million, up 2.31% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.9 million, up from $3.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for FULC reached as high as $26.1 million in Q2 2025 and fell as low as $2.5 million in Q4 2024.
• Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $3.7 million in 2023.
• Across the five-year window, Share-based Compensation slipped 28.18% in 2024 and soared 500.83% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $3.3 million in 2022, then advanced by 5.44% to $3.4 million in 2023, then dropped by 28.18% to $2.5 million in 2024, then advanced by 23.78% to $3.1 million in 2025, then grew by 25.9% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.9 million in Q1 2026, $3.1 million in Q4 2025, and $22.3 million in Q3 2025.